Stocktoria
IMMUCELL CORP /DE/ ICCC
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1987-05-01
IMMUCELL CORP /DE/ financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $27.6M | $26.5M | $17.5M | $18.6M | $19.2M |
| Gross profit | $11.4M | $7.9M | $3.9M | $7.6M | $8.7M |
| R&D expense | $3.0M | $3.9M | $4.4M | $4.5M | $4.2M |
| Operating income | $1.6M | -$1.6M | -$5.7M | -$2.3M | $257,385 |
| Interest expense | — | — | $475,598 | $348,536 | $314,359 |
| Income tax | $11,570 | $10,056 | $4,627 | $7,672 | $9,165 |
| Net income | -$1.0M | -$2.2M | -$5.8M | -$2.5M | -$78,292 |
| EPS (diluted) | $-0.12 | $-0.26 | $-0.75 | $-0.32 | $-0.01 |
| Operating cash flow | $2.5M | $357,903 | -$4.7M | -$1.5M | $954,170 |
| Free cash flow | $1.2M | -$107,822 | -$6.6M | -$5.5M | -$1.7M |
| Cash & equivalents | $3.8M | $3.8M | $978,741 | $5.8M | $10.2M |
| Inventory | $9.3M | $7.1M | $7.8M | $6.0M | $3.1M |
| Total assets | $42.5M | $45.1M | $43.8M | $44.9M | $44.5M |
| Total liabilities | $15.5M | $17.6M | $18.8M | $14.5M | $11.9M |
| Shareholders' equity | $27.1M | $27.5M | $25.0M | $30.4M | $32.6M |
Source: SEC EDGAR filings · CIK 0000811641 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.